BoNT in Postsurgical Pain: Mechanistic and Behavioral Findings from a Porcine SMIR Model
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its...
Adult Tissue and Sex Diversity in SCI: Translational Drug Development
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug development. The clinical need is...
Type 2 Diabetic Neuropathy in the GLP-1 Era
GLP-1 receptor agonists have substantially reshaped the therapeutic landscape for type 2 diabetes and obesity, and the indications now being pursued...
Rethinking the Preclinical Package for Chronic Kidney Disease: Why Pigs belong in the conversation
Drug development for chronic kidney disease has entered a more ambitious phase. SGLT2 inhibitors, non steroidal mineralocorticoid receptor...
CIPN Keeps Failing in the Clinic. The Preclinical Package May Be Why.
Chemotherapy induced peripheral neuropathy remains one of the most underserved symptoms in oncology supportive care. Estimates place the incidence at...
The Diabetic Wound Healing Model That Keeps Earning Its Keep
Chronic wounds in diabetic patients are one of the costliest quietly growing burdens in medicine. Roughly 15 to 25 percent of people with diabetes...
Stroke Models Need Diversity: What Age, Sex, and Comorbidity Change About the Data
Stroke remains one of the highest attrition areas in drug development. Despite decades of preclinical programs showing neuroprotective efficacy in...
Biomarker Strategy in Large Animal Preclinical Studies: What Actually Translates
Biomarkers have become the connective tissue of modern drug development. They anchor mechanism of action claims, support dose selection, enable...
Beyond Rodents: How Translational Pig Models Are De-Risking Pain Programs
The attrition rate for analgesic compounds remains stubbornly high. By some estimates, fewer than 2% of preclinical pain candidates reach approval, a...